Trial Profile
Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROMPT
- Sponsors Biogen
- 26 Dec 2015 According to ClinicalTrials.gov, status changed from not yet recruiting to withdrawn prior to enrolment.
- 18 Jun 2015 New trial record